Healthcare costs of fast-acting insulin analogues versus short-acting human insulin for Danish patients with type 2 diabetes on a basal–bolus regimen

2011 ◽  
Vol 14 (4) ◽  
pp. 477-485
Author(s):  
Torsten E. Christensen ◽  
Jens Gundgaard ◽  
Trine Pilgaard
Keyword(s):  
Type 2 Diabetes ◽  
Human Insulin ◽  
Healthcare Costs ◽  
Insulin Analogues ◽  
Short Acting ◽  
Acting Insulin ◽  
Basal Bolus ◽  
Fast Acting

Long-acting insulin analogues versus NPH human insulin in type 2 diabetes

2008 ◽  
Vol 81 (2) ◽  
pp. 184-189 ◽  
Author(s):  
Matteo Monami ◽  
Niccolò Marchionni ◽  
Edoardo Mannucci
Keyword(s):  
Type 2 Diabetes ◽  
Human Insulin ◽  
Insulin Analogues ◽  
Acting Insulin ◽  
Long Acting

1034-P: Efficacy and Safety of Fast-Acting Insulin Aspart According to Baseline HbA1c in Adults with Type 2 Diabetes Treated with a Basal-Bolus Regimen

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1034-P
Author(s):  
EDWARD FRANEK ◽  
MAGNUS EKELUND ◽  
ÓLÖF THÓRISDÓTTIR ◽  
HAK CHUL JANG ◽  
KATARINA LALIC ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Aspart ◽  
Efficacy And Safety ◽  
Baseline Hba1c ◽  
Acting Insulin ◽  
Basal Bolus ◽  
Fast Acting
Sign in / Sign up

Export Citation Format

Share Document